Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

DMPI $1.35 0.1800 +15.38%
XLRN $31.50 4.0000 +14.55%
GHDX $27.96 3.3100 +13.43%
BPTH $2.66 0.1500 +5.98%
REGN $379.28 18.6400 +5.17%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

IDRA $1.33 -0.1650 -11.07%
BCRX $2.73 -0.2750 -9.17%
CLDX $3.50 -0.3300 -8.62%
RDUS $30.48 -2.5600 -7.75%
SPPI $6.46 -0.5000 -7.18%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | Next > | Last >>

Muscular Dystrophy Drug Falls Short at High-Stakes Meeting

(ABC News/Associated Press) Apr 25, 2016 - Federal health advisers voted against an experimental treatment for muscular dystrophy on Monday, the latest in a series of setbacks for the Sarepta Therapeutics' drug, which has become a rallying point for patients and families affected by the deadly disease.
read article 



New Twist On T-Cell Therapy Puts Leukemia Patients In Remission

(The Seattle Times) Apr 25, 2016 - Scientists at the Fred Hutchinson Cancer Research Center have refined a cancer immunotherapy treatment, resulting in no detectable disease in 27 of 29 patients who had been given months to live, a new study shows.
read article 



Do You Need Complex Surgery? Some Doctors May Not Have Much Practice.

(Washington Post) Apr 25, 2016 - After James Happli of Mosinee, Wis., was diagnosed with pancreatic cancer, he was referred to a surgeon at a local hospital where he had been treated for lymphoma 28 years earlier.
read article (free registration required) 



PerkinElmer and Genome Institute of Singapore Open Joint Research Laboratory to Advance Precision Oncology

(PerkinElmer) Apr 26, 2016 - PerkinElmer, Inc., a global leader focused on improving the health and safety of people and the environment, and the Genome Institute of Singapore (GIS), a biomedical sciences research institute under Singapore’s Agency for Science, Technology and Research (A*STAR), today announced the opening of the PerkinElmer-GIS Centre for Precision Oncology.
read corporate press release 



Evotec and ex scientia Announce Partnership to Discover Bispecific Small Molecule Immuno-Oncology Therapeutics

(Evotec AG) Apr 26, 2016 - Evotec AG and ex scientia Ltd (Dundee, UK) today announced a collaboration with the objective to discover and develop first-in-class bispecific small molecule immuno-oncology therapies.
read corporate press release 



Navigator-specific Interventions and Multidisciplinary Care Team Collaboration Improves Care and Outcomes for Patients with GI Cancers

(Oncology Nurse Advisor) Apr 25, 2016 - The role of the oncology nurse navigator (ONN) is unique in that it allows for assessment and evaluation of systems of care as well as patterns of occurrences within a respective patient population, explained Teresa Labovich, MSN, RN, OCN, of Penrose Cancer Center, Colorado Springs, Colorado, in a presentation at the 2nd annual Oncology Nurse Advisor Navigation Summit.
read article (free registration required) 



Via Oncology Launches Expanded Support for CMMI OCM Practices

(PRWEB) Apr 26, 2016 - Via Pathways and Via Portal have been expanded to support key components for success in the Oncology Care Model from the Centers for Medicare and Medicaid Innovation.
read press release 



Summit Medical Group and MD Anderson Cancer Center Officially Launch Partnership to Bring Premier Cancer Treatment Advances to Northern New Jersey

(Summit Medical Group) Apr 25, 2016 - First-of-its-kind partnership between national cancer care leader and NJ’s largest multispecialty physician group illustrates commitment to deliver integrated world-class cancer care to northern New Jersey.
read press release 



MD Anderson and Helsinn Healthcare SA Enter Strategic Alliance To Improve Life Of Patients Conducting Clinical Studies In Cancer Supportive And Palliative Care

(MD Anderson) Apr 26, 2016 - The University of Texas MD Anderson Cancer Center and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care, today announced that they signed a strategic alliance on a broad, multi-years program of clinical studies in cancer supportive and palliative care.
read press release 



Houston’s MolecularMatch Expands Cancer Patient Treatment Service

(Xconomy Texas) Apr 25, 2016 - Since MolecularMatch launched its web-based service to connect patients to clinical trials two years ago, the startup has received more than 250,000 searches by people seeking cancer treatment.
read article 



Stand Up to Cancer's Next Collaborative Step: Catalyst

(MedPage Today/The Gupta Guide) Apr 25, 2016 - A few days before attendees at the American Association for Cancer Research's annual meeting here heard a high-profile lament about the "marginalization" of basic science at the expense of translational research, Stand Up To Cancer (SU2C) launched the latest phase of its collaborative science model -- Catalyst.
read article (free registration required) 



Hematogenix Laboratory Services, LLC (Hematogenix) - Announces the Launch of two U.S. Food and Drug Administration (FDA) Approved PD-L1 Companion Diagnostic Tests to Help Guide Oncologists Using Immune-Oncology Therapies

(Yahoo! Finance) Apr 25, 2016 - Hematogenix announces the availability of the FDA approved PD-L1 companion diagnostic assays PD-L1 IHC 22C3 pharmDx for KEYTRUDA®, Merck's Anti-PD-1 therapy for metastatic non-small cell lung cancer, and PD-L1 IHC 28-8 pharmDx, a complementary diagnostic assay to support Bristol-Myers Squibb's OPDIVO® anti-PD-1 therapy for non-squamous non-small cell lung cancer.
read article 



Researchers Push For Personalized Tumour Vaccines

(Nature.com) Apr 22, 2016 - Enthusiasm comes amid worries that the therapy may prove too complex to manufacture.
read article 



Gradalis, Inc. Announces Initiation of a Phase 2 Study using Gradalis’ Vigil® Immunotherapy in Combination with Anti-PD-1 Technology to Treat Patients with Advanced Non-Small Cell Lung Cancer

(Yahoo! Finance) Apr 26, 2016 - Gradalis Inc. today announced the initiation of a Phase 2 study for the treatment of patients with advanced non-small cell lung cancer (NSCLC) using its proprietary, personalized cancer vaccine, Vigil® in combination with Bristol-Myers Squibb’s Opdivo® (nivolumab), a monoclonal antibody against programmed death-1 receptor (PD-1).
read article 



3D Printed Tumor-Cloning Device Could Lead To More Effective Cancer Treatments

(InternetMedicine.com) Apr 25, 2016 - Two pharmacy students from North Dakota State University have developed a system for cloning tumors in order to treat individual cancer patients with personalized and more targeted drugs.
read article 



Buffalo State Experts: Does Exercise Benefit Cancer Patients?

(Buffalo State/SUNY) Apr 25, 2016 - A pilot study that looked at the effect of exercise on breast cancer patients taking drugs known as aromatase inhibitors (AIs) showed that exercise diminished the joint pain experienced by some patients.
read article 



New Understanding Of Enzymes Could Help To Develop New Drugs To Treat Diseases From Cancer To Alzheimer's

(University of Leicester [UK]) Apr 25, 2016 - Activation mechanism of class I HDAC complexes by inositol phosphates identified, leading to development of novel peptide-based HDAC inhibitor.
read press release 



Radiology Intelligence Routinely Not Followed in Practice

(Medscape Medical News) Apr 21, 2016 - Approximately one in three radiology recommendations that call for additional clinical action are not abided by, according to a large retrospective study. And nearly half of those directives are not even acknowledged.
read article (free registration required) 



Hidden Costs of Cancer From CT Scans Add Up

(Medscape Medical News) Apr 25, 2016 - The lifetime costs associated with the treatment of cancers induced by the ionizing radiation in CT imaging over just 1 year in the United States add up to hundreds of millions of dollars, new research suggests.
read article (free registration required) 



Risk Factors Identified For Acute Pancreatitis That Can Disrupt Leukemia Treatment

(St. Jude Children's) Apr 25, 2016 - Researchers have identified a rare genetic variation associated with a dramatically increased risk of severe acute pancreatitis in acute lymphoblastic leukemia (ALL) patients treated with the chemotherapy agent asparaginase. St. Jude Children’s Research Hospital led the study, which appears today in the Journal of Clinical Oncology.
read press release 



FDA Approves Cabozantinib for Renal Cell Cancer

(ASCO in Action) Apr 25, 2016 - On April 25, 2016, the U.S. Food and Drug Administration approved cabozantinib (CABOMETYX®, Exelixis, Inc.) for the treatment of advanced renal cell carcinoma in patients who have received prior anti-angiogenic therapy.
read article 



Childhood Leukemia Relapse Rates Improve with High Doses of Chemotherapy Drug Methotrexate

(NYU Langone) Apr 25, 2016 - Study also finds use of the steroid decadron beneficial for younger—but not older—patients.
read press release 



Exelixis Announces FDA Approval of CABOMETYX™ (Cabozantinib) Tablets for Patients with Advanced Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy

(Exelixis) Apr 25, 2016 - CABOMETYX is the first therapy to demonstrate improved overall survival, progression-free survival and objective response rate in a large, randomized phase 3 trial of patients with advanced kidney cancer.
read corporate press release 



FDA Grants Breakthrough Designation to Opdivo for SCCHN

(Healio) Apr 25, 2016 - The FDA granted breakthrough therapy designation to nivolumab for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck who previously received platinum-based therapy.
read article 



Hospitals, Insurers, Seniors Demand Action To Lower Prescription-Drug Costs

(Washington Post) Apr 25, 2016 - A broad coalition including health-care providers, insurers and seniors will propose major changes Monday designed to rein in prescription-drug costs, including a shorter exclusivity period for biotech medications and a requirement that manufacturers disclose more information about pricing.
read article (free registration required)